Imagent Patent Expiration

Imagent is a drug owned by Vesselon Spv Llc. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 25, 2015. Details of Imagent's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5798091 Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
Aug, 2015

(9 years ago)

Expired
US5720938 Systems for the formation of microbubbles
Feb, 2015

(9 years ago)

Expired
US5695741 Stable microbubble precursors
Dec, 2014

(9 years ago)

Expired
US5639443 Stabilized microbubble compositions
Jun, 2014

(10 years ago)

Expired
US5626833 Ultrasound imaging method using microbubbles
May, 2014

(10 years ago)

Expired
US5605673 Stabilized microbubble compositions for ultrasound
Feb, 2014

(10 years ago)

Expired
US6280705 Kits & systems for ultrasonic imaging
Jul, 2013

(11 years ago)

Expired
US6280704 Ultrasonic imaging system utilizing a long-persistence contrast agent
Jul, 2013

(11 years ago)

Expired
US6287539 Methods of imaging using osmotically stabilized microbubble preparations
Jul, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Imagent is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Imagent's family patents as well as insights into ongoing legal events on those patents.

Imagent's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Imagent's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 25, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Imagent Generics:

There are no approved generic versions for Imagent as of now.





About Imagent

Imagent is a drug owned by Vesselon Spv Llc. It is used for medical imaging purposes. Imagent uses Dimyristoyl Lecithin; Perflexane as an active ingredient. Imagent was launched by Vesselon Spv Llc in 2002.

Approval Date:

Imagent was approved by FDA for market use on 31 May, 2002.

Active Ingredient:

Imagent uses Dimyristoyl Lecithin; Perflexane as the active ingredient. Check out other Drugs and Companies using Dimyristoyl Lecithin; Perflexane ingredient

Treatment:

Imagent is used for medical imaging purposes.

Dosage:

Imagent is available in injectable form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.92MG/VIAL;0.092MG/VIAL INJECTABLE Discontinued INTRAVENOUS